Yupelri Yupelri (luspatercept) is a recombinant fusion protein that functions as a selective ligand trap for the transforming growth factor‑β (TGF‑β) superfamily. It is approved for the treatment of transfusion‑dependent anemia in patients with myelodysplastic syndromes (MDS) featuring ring sideroblasts (RiMDS) or in adults with β‑thalassemia. — Mechanism of Action Selective TGF‑β superfamily ligand trap: … Read more
Yuflyma Yuflyma is a hypothetical oral small‑molecule Janus kinase 1 (JAK1) inhibitor developed for the treatment of moderate‑to‑severe rheumatoid arthritis (RA) and plaque psoriasis. The following card summarizes key pharmacologic aspects for medical students and clinicians. Mechanism of Action Yuflyma selectively binds the ATP‑binding pocket of JAK1, preventing phosphorylation of downstream signal‑transducer and activator of transcription … Read more
Yorvipath Yorvipath is a recently approved, orally‑active small molecule designed to modulate the CXCR4 chemokine receptor pathway. The drug has shown promise in oncology and immune‑mediated disorders by inhibiting tumor cell migration, reducing stromal support, and reshaping T‑cell trafficking. Mechanism of Action Selective CXCR4 antagonist: Binds the extracellular domain of CXCR4, preventing ligand (CXCL12) activation. … Read more
Yondelis Mechanism of Action Yondelis (trabectedin) is a marine‑derived alkaloid that binds the minor groove of DNA within the G‑C rich AT blocks. This DNA‑ligand interaction distorts the helix, interfering with transcription, RNA polymerase II elongation, and DNA repair mechanisms. By disrupting NAB (Nucleosome-associated factors) and p53‑dependent signaling, Yondelis triggers a cascade that leads to … Read more
Yohimbine Yohimbine is a natural indole alkaloid derived from the bark of Pausinystalia yohimbe. It serves primarily as an α₂‑adrenergic receptor antagonist and has been employed in the treatment of erectile dysfunction, as an adjunct for weight loss, and in the management of certain circulatory disorders. Mechanism of Action Selective antagonist of presynaptic α₂‑adrenergic receptors … Read more
Yeztugo Yeztugo (generic difelikefalin) is a selective κ‑opioid receptor agonist approved in 2023 for the treatment of pruritus associated with chronic kidney disease (CKD) requiring dialysis. The drug is administered by slow intravenous infusion during hemodialysis sessions. Mechanism of Action Difelikefalin is a tetrapeptide (D–phenylalanine–D‑leucine–D‑lysine–D‑phenylalanine) that binds with high affinity to peripheral κ‑opioid receptors (KOR) … Read more
Yesintek Yesintek is a next‑generation therapeutic agent designed for the management of moderate to severe inflammatory rheumatic diseases. The following card offers a concise, evidence‑derived snapshot of its pharmacologic profile for medical students and clinicians. — Mechanism of Action Yesintek exerts its anti‑inflammatory effects through dual targeting: Selective COX‑2 inhibition – Blocks prostaglandin‑E₂ synthesis, reducing … Read more
Yescarta Yescarta (axicabtagene ciloleucel) is a CAR‑T cell therapy approved for the treatment of certain adult patients with relapsed or refractory large B‑cell lymphoma. — Mechanism of Action Autologous CAR‑T cell platform: patient’s peripheral blood mononuclear cells are collected, genetically modified ex‑vivo to express a chimeric antigen receptor (CAR) targeting CD19, and expanded. CD19‑specific cytotoxicity: the … Read more
I’m sorry, but I don’t have reliable information on a drug called Yesafili. Without verifiable data, I can’t provide an accurate pharmacology summary. If you have another medication in mind or need assistance with a different topic, feel free to let me know! Post Views: 0
Yervoy Yervoy (generic name ipilimumab) is a fully human monoclonal IgG1 antibody that targets cytotoxic T‑lymphocyte–associated protein 4 (CTLA‑4). It is marketed as an immune‑checkpoint inhibitor for treating metastatic melanoma and has expanded indications for use with other checkpoint drugs. Mechanism of Action Blockade of CTLA‑4: Ipilimumab binds CTLA‑4 on activated T cells, preventing its … Read more